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A b s t r a c t  
Investigation of in vitro/in vivo behavior of extended release tablets containing solid dispersions of 
Atorvastatin is the focus of the present research work. Atorvastatin trilayer matrix tablets were 
prepared by direct compression method and consisted of middle active layer with different grades of 
hydroxypropylmethylcellulose (HPMC), ethyl cellulose and Carbopol 934P. Barrier layers are 
prepared with hydrophobic polymers carnauba wax and xanthan gum. Based on the evaluation 
parameters, drug dissolution profile and release order kinetics HF16 was found to be optimized 
formulation. The developed drug delivery system provided prolonged drug release rates over a 
period of 24 h. The release profile of the optimized formulation (HF16) was described by the Zero-
order and best fitted to Higuchi model. FTIR confirmed that there was no chemical interaction 
between drug and excipients used in the formulation. . In vivo bioavailability studies were conducted 
for optimized formulation HF16 and reference standard. The optimized formulation of Atorvastatin 
trilayer matrix tablet was shown significant plasma concentration with extended release and 
maintained for 24 hrs with patient compliance by reducing the dosage frequency, when compared 
with reference standard.  
Keywords: Atorvastatin, Carbopol 934P, Geometric, Trilayer matrix tablet, In-vivo bioavailability 
studies. 
Introduction 
Solid dispersions refer to a system in which hydrophobic drug is 
dispersed in hydrophilic matrix, in order to improve its dissolution 
properties and bioavailability. In solid dispersion, a drug can exist in 
an amorphous or crystalline form in hydrophilic polymeric carriers,  
which results in improved solubility and dissolution rates [1]. 
Many problems are associated with conventional multiple dosing 
regimen of long acting therapy, such as systemic accumulation of 
the drug leading to side effects or toxicities, irregular profile of the 
plasma drug level, and poor patient compliance. Controlled release 
drug delivery systems have the potential of solving these problems. 
Controlled release systems are the methods that can achieve 
therapeutically effective concentration of drug in the systemic 
circulation over an extended period of time with better patient 
compliance [2]. 
There are many ways to design modified release dosage forms for 
oral administration and one of them is multi layered matrix tablet. 
One to three layer matrix tablets is a drug delivery device, which 
comprises a matrix core containing the active solute and one or 
more barriers incorporated during tab letting process [2]. The 
presence of the barriers-layers modifies the hydration/swelling rate 
of the core and reduces the surface area available for drug release 
[3]. The barrier layers delay the interaction of active solute with 
dissolution medium, by limiting the surface available for the solute 
release and at the same time controlling solvent penetration rate 
[4,5]. Hydrophilic polymers have been given considerable attention 
in the formulation of controlled release drug delivery systems for 
various drugs. HPC, HPMC and sodium CMC & Carbopol are a few 
representative examples of the hydrophilic polymers that have been 
extensively used in the formulation of controlled release systems 
[6]. Guar gum is soluble in water, it swells in gastric fluid to produce 
a highly viscous layer around the tablet through which the drug can 
slowly diffuse [7], and is used for the fabrication of matrices with 
uniform drug release characteristics [8,9].  
Geometric technology: There have been different approaches to 
achieve zero-order drug release from dosage forms for sustained 
plasma concentration. Among different approaches to achieve zero-
order release from hydrophilic matrix technologies, multilayer 
matrices have been widely evaluated and developed for commercial 
products under the trade name of Geometric. The technology 
makes use of belayed or trilayer tablets to modulate the release and 
to achieve constant release [10].  
Atorvastatin is a white crystalline powder, molecular formula: 
(C33H34FN2O5)2 Ca.3H2O, molecular weight: 1209.12, 
bioavalability-12%, and half life:  14hrs. It is a selective competitive 
HMG-COA reductase inhibitor drug that lowers the level of 
cholesterol in the blood and triglycerides in patients with 
hypercholesterolemia [11]. 
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The objective of the present study was to develop a trilayered 
controlled release matrix tablet containing Atorvastatin solid 
dispersion with different hydrophobic and hydrophilic polymers to 
achieve zero-order drug release for sustained plasma 
concentration.  
 
Materials and methods 
 
Materials 
 
Atorvastatin calcium pure drug was generous gift from Aurobindo 
Pharma Ltd, Hyderabad, India Carbopol 934P, Ethyl cellulose, 
HPMC K 15 M & HPMC K 100 M was obtained from Rubicon labs, 
Mumbai. Xanthan gum was gifted from MSN Labs Ltd. Hyderabad. 
All other chemicals used were of analytical grade. 
 
Methods 
 
Micromeretic Studies of Atorvastatin  
 
Angle of Repose: In powder frictional forces can be measured with 
the help of angle of repose. Angle of repose is the maximum angle 
which is possible between surface of pile of powder and horizontal 
plane i.e. height. 
tan= h/r 
Θ=tan-1h/r 
Where Θ = Angle of repose 
h= height of pile 
r = radius of pile13  
Carr’s compressibility Index: The propensity of the powder to be 
compressed is measured by compressibility index and it also helps 
in measurement of settling property and inter particulate interaction. 
Carr’s index (%) = ρt – ρo* 100 / ρt 
Where ρt = Tapped density gram/ml 
 ρo = Bulk density gram/ml  
Bulk Dentistry: It is denoted by ρb and is defined as mass of powder 
divided by bulk volume (The United States Pharmacopeial 
Convention Stage 6 Harmonization Official December 1, 2012, 
616.).  
Tapped Density: An increase in bulk density which is attained after 
mechanical tapping in measuring cylinder is called as tapped 
density 
Tapped density= Weight of powder taken/ Tapped Volume.  
Hausner Ratio: The propensity of the powder to be compressed is 
measured by Hausner ratio. Interparticulate interaction and settling 
property can be measured by Hausner ratio. 
Hausner ratio= Tapped density/ Bulk density 
Hausner ratio= Vo/Vf 
Where, Vo= Unsettled apparent volume 
Vf= Final tapped volume[14 ] 
Formulation of controlled release Atorvastatin trilayer 
matrix tablets 
 
The trilayered matrix tablets of Atorvastatin were prepared by direct 
compression method. The first step in the formulation was to 
develop the middle active layer so as to give at least 90%drug 
release during 12hours. The release profile of this layer might not 
be of constant rate type but would be preferably of constantly falling 
rate type. This layer would then be sandwiched between barrier 
layers (Upper & Lower layers) so as to continue the drug release for 
24hours.   
 
Preparation of middle active layer  
 
Sixteen formulations (F1-F16) for active layer were prepared by 
direct compression method using polymers like different HPMC 
grades, Carbobopol 934P and Ethyl Cellulose. All the formulations 
were varied in concentration of polymers, talc (1.5mg) & magnesium 
stearate (1.5mg) constituted in all the formulations.  These materials 
were screened through ≠60 and mixed together in motor by using 
pestle. Final mixtures were compressed by using 12mm diameter 
flat punches on a sixteen station rotary tablet press. Formulation of 
active layer was depicted in Table 1. The prepared tablets were 
subjected to dissolution studies. 
 
Formulation of controlled release Atorvastatin trilayer 
matrix tablets 
 
The trilayered matrix tablets of Atorvastatin were prepared by direct 
compression method. The first step in the formulation was to 
develop the middle active layer so as to give at least 90%drug 
release during 12hours. The release profile of this layer might not 
be of constant rate type but would be preferably of constantly falling 
rate type. This layer would then be sandwiched between barrier 
layers (Upper & Lower layers) to achieve the drug release for 
24hours.  
 
Formulation trails for active layer 
 
Sixteen formulations (F1-F16) for active layer were formulated using 
polymers like different grades of HPMC (HPMC K15M & HPMC 
K100M) and xanthan gum. All the formulations were varied in 
concentration of release retardant polymers and the solid dispersion 
of Atorvastatin [12], talc (1.5mg) & magnesium stearate (1.5mg) 
constituted in all the formulations.  These materials were screened 
through ≠60 and mixed together in motor by using pestle. Final 
mixtures were compressed by using 12mm diameter flat punches 
on a sixteen station rotary tablet press where only one station was 
operative and other station were nullified Formulation F1-F16 
containing drug and other polymers prepared under condition as 
showed in table.  
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Table 1: Formulation trails for active layer (F1-F8) 
INGREDIENTS (mg) F1 F2 F3 F4 F5 F6 F7 F8 
Atorvastatin (Solid dispersion equivalent to 20mg of Atorvastatin) 80 80 80 80 80 80 80 80 
HPMC K 15M 18 21 25 28 30 33 35 38 
HPMC K 100M --- --- --- ---- --- ---- ---- ---- 
Ethyl cellulose 14 11 12 11 10 9 8 8 
Xanthan gum 12 13 10 10 12 9 9 9 
Carbopol 934P 11 10 10 9 8 8 8 6 
Dibasic calcium phosphate 12 12 10 9 7 8 7 6 
Magnesium stearate 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Talc 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
 
Table 2: Formulation trails for active layer (F9-F16) 
INGREDIENTS (mg) F9 F10 F11 F12 F13 F14 F15 F16 
Atorvastatin (Solid dispersion equivalent to 
20mg of Atorvastatin) 
80 80 80 80 80 80 80 80 
HPMC K 15M --- --- --- ---- --- ---- ---- ---- 
HPMC K 100M 18 21 25 28 30 33 35 38 
Ethyl cellulose 14 11 12 11 10 9 8 8 
Xanthan gum 12 13 10 10 12 9 9 9 
Carbopol 934P 11 10 10 9 8 8 8 6 
Dibasic calcium phosphate 12 12 10 9 7 8 7 6 
Magnesium stearate 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Talc 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
 
Preparation of barrier layers 
 
The barrier layers (Upper & Lower layers) was formulated 
employing hydrophobic polymers Carnauba wax and Xanthan gum, 
which include water soluble DCP & EC. Composition of barrier 
layers was depicted in Table 3.  
The procedure tried to make the compacts was via direct 
compressions. For the first procedure the carnauba wax, xanthan 
gum and the filler was mixed in mortar and lubricated with 
magnesium stearate. The mix is then compressed using rotary 
press having 12mm flat tooling. 
 
Table 2: Formulation trails for barrier layer 
Ingredients (mg) A B C D E F G H 
Carnauba wax 5 10 15 20 25 30 35 40 
Xanthan gum 22 24 22 18 20 22 20 20 
Ethyl cellulose 20 16 20 17 18 10 12 12 
Dibasic calcium Phosphate 50 47 40 42 34 35 30 25 
Magnesium stearate 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Talc 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
 
Formulation of Atorvastatin tryilayer tablets 
 
The powder mixtures required for active and barrier layers were 
weighed accurately and thoroughly mixed using mortar and pestle 
for about 20minutes. Initially, the volume of die cavity (12mm, 
round) was adjusted equivalence to the weight of trilayered matrix 
tablets (350mg). Then the pre weighed amount of powder 
equivalent to bottom layer (100mg) was taken and placed in the die 
cavity and slightly compressed for uniform spreading. The upper 
punch was lifted up and 150mg of the drug containing middle active 
layer optimized formulation (F15) was placed over the bottom layer 
in the die cavity and again slightly compressed. The remaining 
volume of the die cavity was filled with pre weighed (100mg) 
amount of powder equivalent to top layer and compressed with the 
full force of compression on rotary tablets press to obtain tri-layered 
tablets. Tri-layered matrix tablets of each composition were 
compressed and tested for their friability, Hardness, drug content 
and drug release characteristics with a suitable number of tablets 
for each test.  
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Table 3: Trilayer tablet composition  
Ingredients (mg) AF16 BF16 CF16 DF16 EF16 FF16 GF16 HF16 
MIDDILE LAYAER (F16) 
Atorvastatin (SD 
equivalent to 20mg) 
80 80 80 80 80 80 80 80 
HPMC K 100M 38 38 38 38 38 38 38 38 
Ethyl cellulose 8 8 8 8 8 8 8 8 
Xanthan gum 9 9 9 9 9 9 9 9 
Carbopol 934P 6 6 6 6 6 6 6 6 
Dibasic calcium 
phosphate 
6 6 6 6 6 6 6 6 
Magnesium stearate 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
BARRIER LAYER (on each side) 
Carnauba wax 5 10 15 20 25 30 35 40 
Xanthan gum 22 24 22 18 20 22 20 20 
Ethyl cellulose 20 16 20 17 18 10 12 12 
Dibasic calcium 
phosphate 
50 47 40 42 34 35 30 25 
Magnesium stearate 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Talc 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Ingredients(mg) AF15 BF15 CF15 DF15 EF15 FF15 GF15 HF15 
MIDDILE LAYAER (F15) 
Atorvastatin SD 320 320 320 320 320 320 320 320 
HPMC K 100M 45 45 45 45 45 45 45 45 
Ethyl cellulose 09 09 09 09 09 09 09 09 
Xanthan gum 08 08 08 08 08 08 08 08 
Sodium CMC 08 08 08 08 08 08 08 08 
Dibasic calcium 
phosphate 
07 07 07 07 07 07 07 07 
Magnesium stearate 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Talc 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
BARRIER LAYER (on each side) 
Carnauba wax 5 10 15 20 25 30 35 40 
Xanthan gum 22 24 22 18 20 22 20 20 
Ethyl cellulose 20 16 20 17 18 10 12 12 
Dibasic calcium 
phosphate 
50 47 40 42 34 35 30 25 
Magnesium stearate 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Talc 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
 
Evaluation of Matrix and Tri-Layered Tablets 
Weight variation 
 
The weight variation test was performed as per the I.P. guidelines. 
Twenty randomly taken tablets were weighed together and the 
average weight was determined. Each tablet was then weighed 
individually and deviation from average weight was calculated. 
 
Hardness 
Hardness of ten randomly picked tablets was determined using 
Monsanto hardness tester. 
 
Friability 
 
A sample of twenty randomly selected tablets were accurately 
weighed and placed in a Roche Friabilator. The Friabilator was 
operated for 4 min at a speed of 25 rpm. The tablets were removed 
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from the Friabilator, de-dusted and reweighed. The percent loss in 
weight due to abrasion and impact was calculated as, 
%Friability= (Loss in weight/ Initial weight) X 100. 
 
Drug content / Assay 
 
20 tablets were accurately weighed and powdered.10mg equivalent 
powder was dissolved in 50ml distilled water and sonicated for 15 
minutes. It was filtered and washed with distilled water. Filtrate and 
washings were combined. Final volume was made up to 100ml with 
distilled water. Absorbance of this solution was determined in a UV 
spectrophotometer at 247nm. Amount of Atorvastatin in tablets was 
calculated by using regression equation. 
 
In-vitro drug release profile 
 
In vitro drug release studies for developed trilayer matrix tablets 
were carried out by using dissolution apparatus II paddle type 
(Electro lab TDL-08L). The drug release profile was studied in 
900ml Phosphate buffer pH 6.8 at 37± 0.50C temperature. The 
amount of drug release was determined by UV visible 
spectrophotometer (Shimadzu UV 1800) at 247nm. 
 
Drug release kinetics  
 
To describe the kinetics of the drug release from matrix tablet, 
mathematical models such as Zero-order, First order and Higuchi, 
models were used. The criterion for selecting the most appropriate 
model was chosen on the basis of the goodness-or fit test. 
 
Pharmacokinetic studies of Atorvastatin 
Animal Preparation  
 
Male rabbits were (weighing 2-3kg) selected for this study, all the 
animals were healthy during the period of the experiment. Animals 
were maintained at room temperature 250C, Relative Humidity 45% 
and 12h alternate light and dark cycle with 100 % fresh air 
exchange in animal rooms, uninterrupted power and water supply 
and rabbits were fed with standard diet and water ad libitum. The 
protocol of animal study was approved by the institutional animal 
ethics committee, CMR College of Pharmacy, Medchel. (IAEC NO: 
CPCSEA/1657/IAEC/CMRCP/Ph.D-15/48). 
 
In vivo study design 
 
The rabbits were randomly divided into two groups each group 
contains six animals. The group A was received prepared 
Atorvastatin matrix tablets (20mg), standard conventional tablets 
(20mg) was administered group B with equivalent dose of animal 
body weight. Blood samples (approximately 0.5ml) were obtained 
with syringes by marginal ear vein at 0, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 
20 and 24h post dose. During collection, blood sample has been 
mixed thoroughly with heparin in order to prevent blood clotting. 
Plasma was separated by centrifugation of the blood at 5000rpm in 
cooling centrifuge for 5min to 10min and stored frozen at −20°C until 
analysis.  
 
Preparation of Plasma Samples for HPLC Analysis  
 
Rabbit plasma (0.5ml) samples were prepared for chromatography 
by precipitating proteins with 2.5ml of ice-cold absolute ethanol for 
each 0.5ml of plasma. After centrifugation the ethanol was 
transferred into a clean tube. The precipitate was re suspended with 
1ml of Acetonitrile by vortexing for 1 min. After centrifugation (5000 
– 6000 rpm for 10min), the Acetonitrile was added to the ethanol 
and the organic mixture was taken to near dryness by a steam of 
nitrogen at room temperature.  
 
HPLC method 
 
Atorvastatin was analyzed on a BDS hypersil C18 column (250 mm× 
4.6 mm, 5μm), applying methanol: water (68:32, v/v) in isocratic 
mode as a mobile phase. Its pH was adjusted to 3.0 with 
trifluroacetic acid at a flow rate of 1ml/min. The peak response was 
monitored at 241nm after injecting a 100μl sample into HPLC 
system. The different HPLC experimental parameters were 
optimized and the method was validated according to standard 
guidelines. A peak area was obtained for Atorvastatin and internal 
standard (naproxen sodium) with 7.41 and 9.64 min retention time, 
respectively [13].  
 
Pharmacokinetic analysis 
 
The pharmacokinetic parameters employed to evaluate were 
maximum plasma concentration (Cmax), time to attain Cmaxi.e., Tmax 
and t ½ values, area under plasma concentration–time curve from 
zero to the last sampling time (AUC0-t), area under plasma 
concentration–time curve from zero to infinity (AUC0-∞). AUC0-twas 
calculated by the linear trapezoidal rule and AUC0-∞ from the 
following formula. 
        AUC0-∞ = AUC0-t + Ct / KE 
 
Results and discussion  
 
Matrix Tablets  
 
The matrix tablets of Atorvastatin were prepared without the barrier 
layers. All the formulation trails were subjected to in vitro dissolution 
to determine the release profile of the drug. 
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Figure 1: In vitro Dissolution profile of F1-F8 Atorvastatin active layer formulations 
 
 
       
Figure  2: In vitro Dissolution profile of F9-F16 Atorvastatin active layer formulations 
 
From the above results, the formulation F16 was decided as 
optimized formulation based on the highest drug release i.e. 
99.8±0.15 up to 12h when compare with other formulations as 
active layer of the trilayer tablets. 
 
Micromeretic studies of Atorvastatin  
 
All the powder mixture belonging to different formulations of 
Atorvastatin trilayer tablets was tested for micrometrics studies like 
bulk density, tapped density, angle of repose and Carr’s index in 
order to determine the flow properties. All the formulations AF16 to 
HF16 showed good flow properties and the results are summarized 
in Table 4. 
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Table 4: Powder flow properties of Atorvastatin trilayer tablets 
 
Powder properties AF16 BF16 CF16 DF16 EF16 FF16 GF16 HF16 
Bulk density (g/cc) 0.647±0.04 0.6882±0.46 0.515±0.02 0.701±0.14 0.599±0.56 0.684±0.78 0.695±0.02 0.714±0.56 
Tapped density(g/cc) 0.581±0.10 0.613±0.93 0.649±0.17 0.667±0.2 0.695±0.53 0.702±0.82 0.733±0.048 0.795±0.93 
Angle of repose (o) 29.69±0.63 34.93±0.66 33.12±0.63 31.89±0.43 30.39±0.66 33.09±0.27 31.15±0.02 27.39±0.66 
Carr’s index 12.01±0.22 11.13±0.93 13.11±0.41 12.29±0.91 13.35±0.94 8.62±0.58 11.28±0.33 13.15±0.94 
All the powder mixture belonging to different formulations was tested for micrometrics studies in order to determine the flow 
properties. All the formulations AF16 to HF16 showed good flow properties. 
 
    Table 5: Evaluation parameters of Atorvastatin trilayer matrix tablets 
Formulation code Thickness (mm) Hardness (kg/cm2) Friability (%) Weight  variation(mg) %Drug content 
AF16 4.10 6.3±0.23 0.34 349±±6.5 98.4 
BF16 4.01 7.6±0.42 0.23 348±4.5 97.3 
CF16 4.14 7.4±0.41 0.35 346±8.5 97.2 
DF16 4.23 7.1±0.32 0.26 349±3.5 98.8 
EF16 4.11 7.2±0.59 0.28 349±1.5 97.5 
FF16 4.02 6.8±0.22 0.26 348±2.5 97.4 
GF16 4.104 7.6±0.55 0.27 347±1.5 97.6 
HF16 4.00 7.3±0.15 0.22 350±0.5 99.3 
The evaluation parameters of all the tablets are within the limits and the hardness ranges in between 6-7kg/cm2. The percentage 
drug content was between 96-99. The Friability, weight variation and thickness was found to be within the limits. Hence all the 
tablets were subjected to in vitro dissolution test to determine the release profiles. 
 
Table 6:  In-vitro   dissolution studies of Atorvastatin Trilayer tablets  
Time (h) AF16 BF16 CF16 DF16 EF16 FF16 GF16 HF16 
Marketed 
product 
1 9.34±0.11 11.26±0.21 13.21±0.04 14.22±0.04 16.32±0.04 18.85±0.04 19.47±0.05 21.02±0.04 96.11±0.02 
2 20.11±0.12 22.28±0.22 23.23±0.05 24.21±0.05 25.32±0.02 26.25±0.05 27.54±0.05 29.12±0.04  
4 31.15±0.03 33.38±0.02 32.28±0.05 36.32±0.04 36.35±0.03 35.23±0.05 36.43±0.05 38.23±0.03  
6 40.25±0.05 42.45±0.03 43.79±0.05 44.15±0.04 45.62±0.04 48.54±0.05 47.25±0.04 49.55±0.05  
8 54.16±0.09 58.98±0.04 48.53±0.05 56.42±0.08 63.32±0.05 48.15±0.04 69.45±0.02 59.99±0.07  
12 60.34±0.05 69.99±0.05 56.75±0.06 74.12±0.05 74.46±0.05 50.75±0.05 70.74±0.03 68.97±0.05  
16 69.75±0.03 75.55±0.04 74.68±0.06 82.24±0.04 84.53±0.04 72.32±0.01 81.65±0.03 79.67±0.05  
20 80.24±0.05 80.20±0.05 82.95±0.07 90.21±0.05 89.15±0.06 87.22±0.05 90.85±0.02 87.88±0.06  
24 86.12±0.04 90.24±0.03 93.45±0.01 91.22±0.02 96.55±0.04 94.24±0.04 95.25±0.02 99.11±0.09  
 
 
 
Figure 3: Comparison of Cumulative percentage drug release of Atorvastatin trilayered matrix tablets and reference standard 
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The In vitro drug profile of Atorvastatin from different formulations 
was carried and the results are depicted in Table 6 & Figure 3.  The 
trilayer tablets extended the drug release up to 24 hrs. The highest 
drug release was found in the formulation HF16 i.e. 99.11±0.09% 
within 24 hrs. HF16 was found to be optimized formulation based on 
the dissolution and other evaluation parameters. The in vitro drug 
release profile from reference standard conventional tablet was 
found to be 96.11±0.02% within 60min. 
 
Release order kinetics of optimized Atorvastatin HF16 
trilayer matrix tablets with reference standard 
 
In the present study drug release mechanism of optimized trilayer 
matrix tablets HF 16 are best fitting to zero order and Higuchi model 
because regression coefficient was seen closest to 1 in these 
models which conforms diffusion assisted mechanism of release. 
The reference standard release was explained by first order kinetics 
as the plot showed highest linearity as the drug release was best 
fitted in first order kinetics. The results are summarized in Table 7. 
 
Table 7: Release order kinetics different formulations of Atorvastatin trilayer tablets 
Formulation code Zero order 
       R2 
First order 
       R2 
Higuchi 
       R2 
Korsmeyer Peppas 
       R2 
Korsmeyer Peppas 
n value 
AF16 0.983 0.865 0.944 0.966 0.578 
BF16 0.985 0.867 0.946 0.968 0.604 
CF16 0.986 0.869 0.947 0.970 0.570 
DF16 0.987 0.870 0.949 0.971 0.634 
EF16 0.988 0.872 0.951 0.973 0.598 
FF16 0.989 0.874 0.952 0.975 0.612 
GF16 0.993 0.875 0.953 0.976 0.635 
HF16 0.994 0.876 0.954 0.977 0.697 
Marketed product 0.958 0.988 0.928 0.905 0.665 
 
Pharmacokinetic studies 
 
 
Figure 4: Plasma Concentrations of Atorvastatin Optimized formulation and Innovator at different time intervals 
 
Table 8: Comparison of pharmacokinetic parameters of Atorvastatin Optimized formulation and Innovator 
Parameters Atorvastatin Optimized formulation  innovator  
Cmax (ng/ml) 92.22±0.05 97.11±0.01 
AUC 0-t (ng h/ml) 1213.65±0.12 842.25±0.12 
AUC0-∞ (ng h/ml) 1516.75±0.14 1045.14±0.22 
Tmax (h) 8.00±0.14 1.02±0.12 
t 1/2 (h) 10.5±0.014 2.50±0.05 
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Bioavailability Parameters 
 
Mean plasma concentration profiles of prepared Atorvastatin 
optimized formulation and marketed product are presented in Figure 
4. Atorvastatin optimized formulation exhibited as sustained release 
in vivo when compared with marketed tablet. All the 
pharmacokinetics parameters displayed in Table 8. In this study the 
prolonged drug absorption was achieved with the test formulation. 
The average peak concentration of the reference formulation was 
higher than that of the test (92.22±0.05ng/ml for the test formulation 
versus 97.11±0.01ng/ml for the reference). AUC is an important 
parameter in evaluating bioavailability of drug from dosage form, as 
it represents the total integrated area under the blood concentration 
time profile and represents the total amount of drug reaching the 
systemic circulation after oral administration. AUC0-inf for optimized 
formulation was higher (1516.75±0.14ng h/ml) than the innovator 
product 1045.14±0.22ng h/ml. Statistically, AUC0-t of the optimized 
preparation was significantly higher (p<0.05) as compared to 
innovator product. The results indicated that the test formulation 
could increase the bioavailability of Atorvastatin in vivo effectively. 
In this study, the Atorvastatin matrix tablets produce higher 
bioavailability than that of a marketed product. 
 
 
Summary and conclusion 
 
In the present study, the proposed solid dispersions of Atorvastatin 
containing trilayer tablets were confirmed to be a successful tool for 
prolonged period of time up to 24 h.  The study proves that the 
potential use of controlled release trilayer matrix tablets as an 
efficient strategy for the oral delivery of Atorvastatin prepared by 
direct compression technique using different polymers combination. 
Based on the evaluation parameters, drug dissolution profile and 
release drug kinetics HF16 was found to be optimized formulation. 
The drug release from HF16 was found to fit Zero order and best 
fitted to Higuchi’s model confirming to be diffusion assisted 
mechanism. In vivo bioavailability studies were conducted for 
optimized formulation HF16 and reference standard. The optimized 
formulation of Atorvastatin trilayer matrix tablet was shown 
significant plasma concentration with controlled release and 
maintained for 24 hrs with patient compliance by reducing the 
dosage frequency, when compared with reference standard. 
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